The current price-band grouping rule for listed generics has resulted in a distortion in the market, with 80 products in the lowest price range given higher NHI prices in the FY2016 price revision, Mitsuo Sawai, president of Japanese generic major…
To read the full story
Related Article
ORGANIZATION
- PhRMA Welcomes Honebuto, Prods Japan to Launch Reform This Year
July 22, 2026
- JPMA Backs Honebuto 2026 Innovation Agenda
July 21, 2026
- JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
- WHO Opens Tokyo Hub to Help Health Systems in Developing Nations
July 16, 2026
- FIRM Unveils Vision 2030 to Bolster Japan’s Regenerative Medicine Industry
July 15, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





